Microbix Biosystems (TSX:MBX) has appointed Cameron Groome as its president and CEO, with Vaughn Embro-Pantalony retiring from those positions but remaining an executive director, working closely with Mr. Groome to ensure a smooth leadership transition.
Cameron Groome has been in the life sciences industry for more than 25 years, as a CEO, director, advisor, senior executive, investment banker and equity research analyst.
He has been successful in operating, advising, financing and analyzing life sciences companies and has been a member of the board and audit committee of Microbix for the past five years.
In a statement, William Gastle, founder and executive chairman of Microbix, said Mr. Groome’s “abilities and knowledge of life sciences and Microbix should help drive us to greater success.”
Mr. Embro-Pantalony said it has been a privilege to lead Microbix and work with such a dedicated and passionate group of professionals. “It is with pride that I leave the CEO role with Microbix well-established as a global leader in the production of viruses for use in diagnostic tests or for quality control validation.”
Mr. Groome said Microbix has exciting opportunities for growth, including in its virology business, with its thrombolytic drug, Kinlytic Urokinase and for Lumisort cell-sorting technology.